Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study (vol 11, e0164455, 2016)

被引：0

作者：

Troya, Jesus ^{[1
]}

Ryan, Pablo ^{[1
]}

Ribera, Esteban ^{[1
]}

Podzamczer, Daniel ^{[1
]}

Hontanon, Victor ^{[1
]}

Alberto Terron, Jose ^{[1
]}

Boix, Vicente ^{[1
]}

Moreno, Santiago ^{[1
]}

Barrufet, Pilar ^{[1
]}

Castano, Manuel ^{[1
]}

Carrero, Ana ^{[1
]}

Jose Galindo, Maria ^{[1
]}

Suarez-Lozano, Ignacio ^{[1
]}

Knobel, Hernando ^{[1
]}

Raffo, Miguel ^{[1
]}

Solis, Javier ^{[1
]}

Yllescas, Maria ^{[1
]}

Esteban, Herminia ^{[1
]}

Gonzalez-Garcia, Juan ^{[1
]}

Berenguer, Juan ^{[1
]}

Imaz, Arkaitz ^{[1
]}

机构：

[1] Hosp Univ Gregorio Maranon, Madrid, Spain

来源：

PLOS ONE | 2017年 / 12卷 / 02期

关键词：

D O I：

10.1371/journal.pone.0172184

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

引用

页数：1

共 25 条

[21] Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
Orrell, Catherine
Hagins, Debbie P.
Belonosova, Elena
Porteiro, Norma
Walmsley, Sharon
Falco, Vicenc
Man, Choy Y.
Aylott, Alicia
Buchanan, Ann M.
Wynne, Brian
Vavro, Cindy
Aboud, Michael
Smith, Kimberly Y.
LANCET HIV, 2017, 4 (12): : E536 - E546
[22] Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
Moyle, Graeme
Assoumou, Lambert
de Castro, Nathalie
Post, Frank A.
Curran, Adrian
Rusconi, Stefano
De Wit, Stephane
Stephan, Christoph
Raffi, Francois
Johnson, Margaret
Masia, Mar
Vera, Jaime
Jones, Bryn
Grove, Richard
Fletcher, Carl
Duffy, Annie
Morris, Kellie
Pozniak, Anton
LANCET HIV, 2024, 11 (03): : e156 - e166
[23] Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
Perez-Molina, Jose A.
Rubio, Rafael
Rivero, Antonio
Pasquau, Juan
Suarez-Lozano, Ignacio
Riera, Melcior
Estebanez, Miriam
Santos, Jesus
Sanz-Moreno, Jose
Troya, Jesus
Marino, Ana
Antela, Antonio
Navarro, Jose
Esteban, Herminia
Moreno, Santiago
LANCET INFECTIOUS DISEASES, 2015, 15 (07): : 775 - 784
[24] Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT):48 week results from a randomised, open-label, non-inferiority trial (vol 15, pg 775, 2015)
Perez-Molina, J. A.
Rubio, R.
Rivero, A.
LANCET INFECTIOUS DISEASES, 2015, 15 (09): : 998 - 998
[25] Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials (vol 393, pg 143, 2019)
Cahn, P.
Madero, J. S.
Arribas, J. R.
LANCET, 2019, 393 (10167): : 132 - 132

← 1 2 3 →